Nick Leschly, MBA, has served as our Chief Bluebird since September 2010. Bluebird bio (BLUE) is a clinical-stage company committed to developing both transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer. The driving vision is to make hope a reality for many patients and their families by bringing True Blue (an ideal state for patients) to life through Blue Mojo (innovative, resilient, and purpose–driven culture).
Formerly, Mr. Leschly was a partner and founding member of Third Rock Ventures in 2007. He played an integral role in the overall formation, development, and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE, a multiple myeloma treatment. Mr. Leschly also founded and served as chief executive officer of MedXtend Corporation. He received his Bachelor of Science in molecular biology from Princeton University and his MBA from Wharton Business School. He serves on the board of Biotechnology Innovation Organization (BIO), Synlogic (SYBX), and Proclara Biosciences. He also serves on the advisory boards for Princeton University’s Molecular Biology Department and for the Special Olympics of Massachusetts. Mr. Leschly is extremely happily married to his high school sweetheart and has five teenage daughters.